Explore FR alpha

FRα protein expression may help inform patient care in ovarian cancer.^1-3

Expand your knowledge of FRα IHC detection and assess staining patterns in ovarian cancer.

Ovarian Cancer Biomarkers

Ovarian cancer is often characterized by late stage diagnosis, high rates of recurrence, and a lack of robust, validated screening tools.¹ Explore the current biomarker landscape in ovarian cancer and review information.

Learn More

Case Atlas

Explore a collection of ovarian cancer cases with a wide range of FRα staining patterns. Learn more about assessing challenging cases and examine staining patterns on whole-slide images.

Discover Cases

Self-Assessment

Put your knowledge to the test across 5 different cases spanning the range of FRα expression.

Practice Assessment

Resource Library

View a collection of downloadable resources summarizing FRα assessment, challenging staining patterns, as well as ovarian cancer facts.

View Resources

FRα=folate receptor alpha; IHC=immunohistochemistry.

References

Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353. doi:10.1038/s41416-022-02031-x.
Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553-52574. doi:10.18632/oncotarget.9651.

Mai J, Wu L, Yang L, et al. Therapeutic strategies targeting folate receptor α for ovarian cancer. Front Immunol. 2023;14:1254532. doi:10.3389/fimmu.2023.1254532.

Developed and authored by AbbVie US Medical Affairs.

ABBV-US-01960-MC, v1.0
Approved: August 2025

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.